Related references
Note: Only part of the references are listed.Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Hans Gelderblom et al.
BRITISH JOURNAL OF CANCER (2020)
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Venkatesh Pilla Reddy et al.
CLINICAL CANCER RESEARCH (2020)
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
James Lin Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).
Ping Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Maud Toulmonde et al.
CLINICAL CANCER RESEARCH (2019)
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Cesar Serrano et al.
CLINICAL CANCER RESEARCH (2019)
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
Jason G. Kettle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
1603OInitial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens
S George et al.
ANNALS OF ONCOLOGY (2018)
1623PCorrelation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib
S George et al.
ANNALS OF ONCOLOGY (2018)
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
Bruno Vincenzi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors
Amber E. Bannon et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri et al.
Journal of the National Comprehensive Cancer Network (2017)
The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).
Clara Marie Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors
Larissa Merten et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST
Monica Brenca et al.
JOURNAL OF PATHOLOGY (2016)
FGFR1 and NTRK3 actionable alterations in Wild-Type gastrointestinal stromal tumors
Eileen Shi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
David M. Hyman et al.
DRUG DISCOVERY TODAY (2015)
Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
Leili Ran et al.
CANCER DISCOVERY (2015)
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
K. N. Ganjoo et al.
ANNALS OF ONCOLOGY (2014)
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
A. Adenis et al.
ANNALS OF ONCOLOGY (2014)
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Thomas Van Looy et al.
CLINICAL CANCER RESEARCH (2014)
Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor
Teresa S. Kim et al.
CLINICAL CANCER RESEARCH (2014)
A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
Y-K Kang et al.
BRITISH JOURNAL OF CANCER (2013)
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Giuseppe Floris et al.
CLINICAL CANCER RESEARCH (2013)
Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA
Jacqueline Maier et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
S. H. Park et al.
INVESTIGATIONAL NEW DRUGS (2012)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
H. Joensuu et al.
BRITISH JOURNAL OF CANCER (2011)
Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
Akira Sawaki et al.
CANCER (2011)
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
Tara C. Gangadhar et al.
CLINICAL CANCER RESEARCH (2011)
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
J. C. Trent et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P. Schoffski et al.
ANNALS OF ONCOLOGY (2010)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors A Study of 1840 Cases
Markku Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
B. Liegl et al.
JOURNAL OF PATHOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S. Bauer et al.
ONCOGENE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors:: A study by the Spanish Group for Sarcoma Research (GEIS)
J Martín et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
